ADAMAS PHARMACEUTICALS INC's ticker is ADMS and the CUSIP is 00548A106. A total of 85 filers reported holding ADAMAS PHARMACEUTICALS INC in Q2 2016. The put-call ratio across all filers is - and the average weighting 0.6%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2019 | $111,000 | -35.8% | 21,790 | -22.0% | 0.00% | – |
Q2 2019 | $173,000 | -26.1% | 27,936 | +1.9% | 0.00% | – |
Q4 2018 | $234,000 | -72.8% | 27,411 | -36.2% | 0.00% | -100.0% |
Q3 2018 | $860,000 | -25.8% | 42,959 | -4.3% | 0.00% | 0.0% |
Q2 2018 | $1,159,000 | -57.2% | 44,879 | -60.4% | 0.00% | -66.7% |
Q1 2018 | $2,705,000 | -38.3% | 113,188 | -12.5% | 0.00% | -25.0% |
Q4 2017 | $4,385,000 | +57.1% | 129,391 | -1.9% | 0.00% | +33.3% |
Q3 2017 | $2,792,000 | +46.9% | 131,887 | +21.3% | 0.00% | +50.0% |
Q2 2017 | $1,901,000 | -2.8% | 108,709 | -2.8% | 0.00% | -33.3% |
Q1 2017 | $1,956,000 | +162.2% | 111,788 | +153.3% | 0.00% | +200.0% |
Q4 2016 | $746,000 | -39.4% | 44,134 | -41.2% | 0.00% | -50.0% |
Q3 2016 | $1,232,000 | +12.4% | 75,099 | +3.8% | 0.00% | 0.0% |
Q2 2016 | $1,096,000 | +4.8% | 72,376 | +0.0% | 0.00% | 0.0% |
Q1 2016 | $1,046,000 | – | 72,343 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
GREAT POINT PARTNERS LLC | 2,601,351 | $43,963,000 | 9.03% |
Granite Point Capital Management, L.P. | 256,031 | $4,327,000 | 3.45% |
Opaleye Management Inc. | 285,000 | $4,817,000 | 2.84% |
Brenner West Capital Advisors | 1,221,463 | $20,643,000 | 2.28% |
ARMISTICE CAPITAL, LLC | 536,000 | $9,058,000 | 2.14% |
NEXTHERA CAPITAL LP | 151,670 | $2,563,000 | 1.50% |
INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 185,234 | $3,130,000 | 1.41% |
Cheyne Capital Management (UK) LLP | 144,765 | $2,448,000 | 1.38% |
SPHERA FUNDS MANAGEMENT LTD. | 270,000 | $4,563,000 | 1.16% |
Mosaic Family Wealth, LLC | 123,314 | $2,084,000 | 0.96% |